Skip to main content
Robert Hopkin, MD, Medical Genetics, Cincinnati, OH, Cincinnati Children's Hospital Medical Center

RobertJHopkinMDFAAP, FACMGG

Medical Genetics Cincinnati, OH

Clinical Genetics

Professor, Clinical Pediatrics, University of Cincinnati College of Medicine Department of Pediatrics

Dr. Hopkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hopkin's full profile

Already have an account?

Summary

  • My key interests include: Diagnosis and management of rare diseases, clinical trials, lysosomal disease, differences in sexual development, prenatal and fetal diagnostics, and medical education

Education & Training

  • Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical CenterResidency, Medical Genetics and Genomics, 1994 - 1997
  • Phoenix Children's Hospital
    Phoenix Children's HospitalResidency, Pediatrics, 1990 - 1994
  • University of Nevada, Reno School of Medicine
    University of Nevada, Reno School of MedicineClass of 1990
  • Brigham Young University
    Brigham Young UniversityB.S., Zoology, 1986

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 2021 - 2025
  • OH State Medical License
    OH State Medical License 1994 - 2024
  • AZ State Medical License
    AZ State Medical License 1993 - 1994
  • American Board of Pediatrics Pediatrics
  • American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Awards, Honors, & Recognition

  • Teacher of the year Cincinnati Children's Hospital Medical Center, 2001
  • Outstanding Medical Research While in Pediatric Residency Training 1994

Publications & Presentations

PubMed

Journal Articles

  • Cardiopulmonary Fitness Assessment on Maximal and Submaximal Exercise Testing in Patients with Fabry Disease  
    John L Jefferies, Clifford Chin, Robert J Hopkin, Adam W Powell, American Journal of Medical Genetics Part A
  • Keutel syndrome: Report of two novel MGP mutations and discussion of clinical overlap with arylsulfatase E deficiency and relapsing polychondritis  
    Weaver KN, El Hallek M, Sund KL, Henrickson M, Del Gaudio D, Yuksel A, Acar GO, Bober MB, Kim J, Boyadjiev SA, Am J Med Genet A, 1/1/2014
  • Delineating the phenotype of 1p36 deletion in adolescents and adults  
    Brazil A, Stanford K, Smolarek T, Am J Med Genet A, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Two Cases of Maternal UPD(16) : Phenotypic Evidence of an Imprinting Disorder Affecting Chromosome 16
    Lesmana H, Dyer L, Smolarek TA, ACMG, 1/1/2015
  • Improving Adherence to the Health Supervision Guidelines for Children with Down Syndrome
    Stephanie Santoro, Lisa J. Martin, Stephen I. Pleatman, ACMG, 1/1/2015
  • Case Study: Phenotypic evidence for skewed X-inactivation in two siblings with an unbalanced X;22 translocation
    Balow SA, Lesmana H, Leslie ND, Smolarek T, ACMG, 1/1/2015
  • Join now to see all

Other

  • Cytochrome P450 Oxidoreductase Deficiency 
    Cragun D, Hopkin RJ, GeneReviews at GeneTests: Medical Genetics Information Resource
    1/1/2005

Press Mentions

  • Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
    Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry DiseaseFebruary 22nd, 2023
  • Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts Say
    Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts SayFebruary 5th, 2021
  • Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
    Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileFebruary 6th, 2024

Other Languages

  • French

Hospital Affiliations